+30.4%
GSK vs LCID
-71.9%
+102.3%
-18.5%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | LCID | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.9% | +1.7% | -3.7% | -2.0% |
| 7D | -1.8% | -6.6% | +4.8% | -1.5% |
| 30D | -2.2% | -30.1% | +28.0% | -0.2% |
| 3M | -1.8% | -17.6% | +15.8% | -1.7% |
| 6M | -10.6% | -54.4% | +43.8% | -6.7% |
| YTD | +4.4% | -55.7% | +60.1% | +8.7% |
| 1Y | +30.4% | -71.0% | +101.5% | +36.5% |
| All | +30.4% | -71.9% | +102.3% | +36.5% |
Cumulative growth
Daily Returns
Daily percentage return beside LCID.
Daily Out/Under-Performance
Portfolio return minus LCID return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × LCID return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded LCID wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling